|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2023―Aug―30 |
Autoimmune hepatitis following mRNA COVID-19 vaccine* |
Ahmed Zaiem, Khouloud Ferchichi, Ghozlane Lakhoua, Widd Kaabi, Imen Aouinti, Sana Rebii Debbiche, et al. (+4) Sarrah Kastalli, Lamia Kallel, Ons Charfi, Sihem EL Aidli |
2 |
[GO] |
2023―Jun―15 |
Augmentation des surdoses et décès en lien avec la consommation de méthadone durant la crise sanitaire liée au COVID-19 en 2020 |
Elisabeth Frauger, Nathalie Fouilhé, Clémence Lacroix, Amélie Daveluy, Reynald Le Boisselier, Célian Bertin, et al. (+11) Bruno Revol, Louise Carton, Cécile Chevalier, Céline Eiden, Valérie Gibaja, Aurélie Aquizerate, Leila Chaouachi, Emilie Bouquet, Anne Roussin, Michel Mallaret, Joëlle Micallef |
3 |
[GO] |
2023―Jun―07 |
Acute angle closure glaucoma following COVID-19 vaccination* |
Yasmine Salem Mahjoubi, Israa Dahmani, Ines Souilem, Imen Aouinti, Sarrah Kastalli, Riadh daghfous, Sihem El Aidli |
4 |
[GO] |
2023―Jun―07 |
Hydroxychloroquine and COVID-19: the endgame! |
Dominique Deplanque |
5 |
[GO] |
2023―Jun―02 |
Why the article that led to the widespread use of hydroxychloroquine in COVID-19 should be retracted? |
Damien Barraud, Lonni Besancon, Elisabeth M Bik, Eric Billy, Franck Clarot, Fabrice Frank, et al. (+7) Anthony Guihur, David Hajage, Karine Lacombe, Hervé Maisonneuve, Mathieu Molimard, Matthieu Mulot, Alexander Samuel |
6 |
[GO] |
2023―May―25 |
Response to Letter “Only blames SARS-CoV-2 vaccination for facial palsy after alternative etiologies have been ruled out” |
Morgane Chamboux, Corinne Simon, Frédérique Beau-Salinas, Anaïs Maurier, Marie Sara Agier, Eve Marie Thillard, et al. (+2) Bérenger Largeau, Annie Pierre Jonville-Bera |
7 |
[GO] |
2023―May―17 |
Only blame SARS-CoV-2 vaccination for facial palsy after alternative etiologies have been ruled out |
Josef Finsterer, Fulvio A Scorza |
8 |
[GO] |
2023―Mar―07 |
Role of spontaneous reporting in investigating the relationship between mRNA COVID-19 vaccines and myocarditis: the French perspective |
Francesco Salvo, Antoine Pariente, Marie Blanche Valnet-Rabier, Milou-Daniel Drici, Clement Cholle, Clement Mathieu, et al. (+5) Allison Singier, Haleh Bagheri, Martine Tebacher, Joelle Micallef, Sophie Gautier |
9 |
[GO] |
2023―Mar―07 |
Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: a win-win bet with Health Authorities! |
Annie Pierre Jonville-Bera, Sophie Gautier, Joëlle Micallef, Nathalie Massy, Marina Atzenhoffer, Aurélie Grandvuillemin, Milou-Daniel Drici |
10 |
[GO] |
2023―Feb―22 |
French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19) |
Claire de Canecaude, François Montastruc, Sandrine Bergeron, Paola Sanchez Pena, Aurélie Grandvuillemin |
11 |
[GO] |
2023―Feb―22 |
Pharmacovigilance des médicaments et des vaccins contre la COVID-19 durant la pandémie: comment le Réseau français des centres régionaux de pharmacovigilance a relevé le défi? |
Annie Pierre Jonville-Bera, Sophie Gautier, Joëlle Micallef, Nathalie Massy, Marina Atzenhoffer, Milou-Daniel Drici, Aurélie Grandvuillemin |
12 |
[GO] |
2023―Feb―16 |
Peripheral facial palsy post SARS-CoV-2 vaccine: a regional pharmacovigilance cases series |
Morgane Chamboux, Corinne Simon, Frédérique Beau-Salinas, Anaïs Maurier, Marie Sara Agier, Eve Marie Thillard, et al. (+2) Bérenger Largeau, Annie Pierre Jonville-Bera |
13 |
[GO] |
2023―Jan―21 |
Covid-19 Et Vaccins À Adénovirus: Expérience Française De Suivi Renforcé De Pharmacovigilance |
Nathalie Massy, Marina Atzenhoffer, Charlène Boulay, Pauline Pecquet, Fanny Ledys, Jean-Luc Cracowski, et al. (+3) Kamel Masmoudi, Marion Lepelley, Valérie Gras Champel |
14 |
[GO] |
2023―Jan―20 |
Contribution of real-life studies in France during the COVID-19 pandemic and for the national pharmaco-epidemiological surveillance of COVID-19 vaccines |
Mahmoud Zureik, François Cuenot, Alain Weill, Rosemary Dray-Spira |
15 |
[GO] |
2023―Jan―20 |
Impact of coronavirus disease 2019 on contraception use in France |
Noemie Roland, Jerome Drouin, David Desplas, Lise Duranteau, Francois Cuenot, Rosemary Dray-Spira, et al. (+2) Alain Weill, Mahmoud Zureik |
16 |
[GO] |
2023―Jan―20 |
Pharmacovigilance follow-up of patients in the context of the COVID 19 pandemic |
Aurélie Grandvuillemin, Fanny Rocher, Marie Blanche Valnet-Rabier, Milou-Daniel Drici, Anne Dautriche |
17 |
[GO] |
2022―Dec―10 |
Impact des confinements sur les hospitalisations survenues dans un contexte d’usage de substances psycho-actives en France selon l’âge pendant la pandémie de COVID-19 |
Justine Perino, Hanta Ramaroson, Nathalie Ong, Julien Bezin, Véronique Gilleron, Amélie Daveluy, Marie Tournier |
18 |
[GO] |
2022―Dec―10 |
Chronic spontaneous urticaria following vaccination against SARS-CoV-2 |
Ahmed Zaiem, Yasmine Salem Mahjoubi, Imen Aouinti, Ghozlane Lakhoua, Widd Kaabi, Sarrah Kastalli, et al. (+3) Sana Rebii Debbiche, Ons Charfi, Sihem El Aidli |
19 |
[GO] |
2022―Dec―10 |
The need to shed light on potential insidious SARS-CoV-2 post-vaccination pituitary lesions |
Ach Taieb, Euch Mounira El |
20 |
[GO] |
2022―Dec―10 |
Central diabetes insipidus, hypophysitis and SARS-CoV-2 vaccine: correspondence |
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit |
21 |
[GO] |
2022―Oct―31 |
Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV2 pandemic |
Pauline Lory, Sandrine Combret, Joelle Michot, Gwenaelle Veyrac, Laurent Chouchana, Aurélie Grandvuillemin |
22 |
[GO] |
2022―Oct―06 |
Central diabetes insipidus revealing a hypophysitis induced by SARS-CoV-2 vaccine |
Taieb Ach, Fatma Kammoun, Hamza El Fekih, Nassim Ben Haj Slama, Siwar Kahloun, Fatma Ben Fredj, et al. (+2) Chédia Laouani, Koussay Ach |
23 |
[GO] |
2022―Aug―01 |
Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses’ infections |
Zineb Ghrieb, Maud Salmona, David Michonneau, Charles De Saisset, Souhil Allaoua, Jean-Jacques Kiladjian, et al. (+3) Jérôme Le Goff, Anne Bergeron, Lina Benajiba |
24 |
[GO] |
2022―Jul―13 |
The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans. Effects of the AstraZeneca COVID-19 vaccination |
Rafael Dal-Ré |
25 |
[GO] |
2022―Jun―30 |
Hospitalisations après consommation de substances psychoactives pendant la pandémie de Covid-19 |
Claire Dumoulin, Nathalie Ong, Hanta Ramaroson, Louis Létinier, Ghada Miremont-Salamé, Véronique Gilleron, et al. (+2) Amélie Daveluy, Justine Perino |
26 |
[GO] |
2022―May―19 |
COVID-19: GLOBAL INEQUALITY IN SCIENCE |
Bakthavachalam Elango |
27 |
[GO] |
2022―May―07 |
Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic |
Émilien Schultz, Léo Mignot, Jeremy Ward, Daniela Boaventura, Christian Chabannon, Julien Mancini |
28 |
[GO] |
2022―Apr―27 |
Adverse drug reactions and ivermectin in COVID-19 |
Jean-Louis Montastruc |
29 |
[GO] |
2022―Apr―26 |
Cluster headache after COVID-19 vaccination with Comirnaty: a signal in pharmacovigilance database* |
Michaël Rochoy, Eric Billy, Franck Clarot, Victor Dumortier, Sophie Gautier, Romain Barus |
30 |
[GO] |
2022―Apr―20 |
Adverse drug reactions associated with ivermectin use for COVID-19 reported in the WHO’s pharmacovigilance database |
Jeremy T. Campillo, Jean-Luc Faillie |
31 |
[GO] |
2022―Apr―20 |
Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT) |
Florian Lemaitre, Matthieu Grégoire, Caroline Monchaud, Stéphane Bouchet, Béatrice Saint-Salvi, Elisabeth Polard, et al. (+12) Sihem Benaboud, Laurent Chouchana, Jean-Luc Cracowski, Milou-Daniel Drici, Rodolphe Garraffo, Romain Guilhaumou, Annie-Pierre Jonville-Bera, Mathieu Molimard, Patric Muret, Gilles Peytavin, Vincent Richard, Caroline Solas |
32 |
[GO] |
2021―Dec―28 |
Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic |
Pauline Lory, Jeffrey Lombardi, Clémence Lacroix, Paola Sanchez-Pena, Serena Romani, Aurélie Grandvuillemin |
33 |
[GO] |
2021―Dec―04 |
Lessons from the COVID-19 pandemic |
Philippe Lechat |
34 |
[GO] |
2021―Oct―25 |
A historical cohort stuy to investigation of statins safety in COVID-19 hospitalized patients |
Saeed Nateghi, Mohammad Mahmoudi Gomari, Hadiseh Hosamirudsari, Behnam Behnoush, Asma Razmjoofard, Goli Azimi, et al. (+3) Shokooh Ordookhani, Ali Jafarpour, Neda Faraji |
35 |
[GO] |
2021―Oct―08 |
Peptides-based therapeutics: emerging potential therapeutic agents for COVID-19 |
Jagat Narayan Shah, Guang-Qin Guo, Anand Krishnan, Muthusamy Ramesh, Naresh Kumar Katari, Mohd Shahbaaz, et al. (+3) Magda H. Abdellattif, Sachin Kumar Singh, Kamal Dua |
36 |
[GO] |
2021―Jul―27 |
Balancing the reactogenicity of the ChAdOx1 nCov-19 vaccine against SARS-CoV-2 and the urgent need of a large immunization in healthcare workers |
Laurent Chouchana, Etienne Canouï, Rui Batista, Adrien Contejean, Alain Cariou, Jean Marc Treluyer, Caroline Charlier |
37 |
[GO] |
2021―Jun―01 |
COVID-19 vaccines and pregnancy: what do we know? |
Judith Cottin, Justine Benevent, Sophie Khettar, Isabelle Lacroix |
38 |
[GO] |
2021―May―28 |
COVID-19 vaccines: a perspective from social pharmacology |
Jean-Louis Montastruc, Margaux Lafaurie, Claire de Canecaude, François Montastruc, Haleh Bagheri, Geneviève Durrieu, Agnès Sommet |
39 |
[GO] |
2021―May―28 |
COVID-19: Pharmacology has kept the science ship running during the storm |
Mathieu Molimard, Vincent Richard, Jean-Luc Cracowski |
40 |
[GO] |
2021―May―12 |
Efficacy of Covid-19 vaccines: from clinical trials to real life |
Dominique Deplanque, Odile Launay |
41 |
[GO] |
2021―May―07 |
French organization for the Pharmacovigilance of COVID-19 vaccines: a major challenge |
Clémence Lacroix, Francesco Salvo, Valérie Gras-Champel, Sophie Gautier, Nathalie Massy, Marie-Blanche Valnet-Rabier, et al. (+6) Aurélie Grandvuillemin, Céline Mounier, Mehdi Benkebil, Antoine Pariente, Annie-Pierre Jonville-Bera, Joëlle Micallef |
42 |
[GO] |
2021―May―07 |
Evaluation of Covid-19 vaccines: pharmacoepidemiological aspects |
Antoine Pariente, Julien Bezin |
43 |
[GO] |
2021―Apr―29 |
Eruption eczématiforme après le vaccin par Pfizer-BioNTech COVID-19* |
Nihal Bekkali, Tanguy Allard, Eric Estève, Céline Lengellé |
44 |
[GO] |
2021―Apr―02 |
Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell’s palsy |
Thomas Soeiro, Francesco Salvo, Antoine Pariente, Aurélie Grandvuillemin, Annie-Pierre Jonville-Béra, Joëlle Micallef |
45 |
[GO] |
2021―Mar―06 |
Pneumopathie médicamenteuse ou liée à la COVID-19: un train peut en cacher un autre! |
Mélanie Vasseur, Marine Tambon, Mireille Gony, Nicolas Lebrun, Haleh Bagheri |
46 |
[GO] |
2021―Feb―16 |
Un exemple de réorganisation dans le fonctionnement d’un Centre d’investigations cliniques en période de confinement national suite à la pandémie COVID-19 |
Zineb Ghrieb, Souhil Allaoua, Jin Huang, Nathalie Langner, Florène François, Corinne Maréchal, et al. (+8) Majdi Jebali, Céleste Lebbé, Abdennour Chellah, Anne Bergeron, Jean-Jacques Kiladjian, Rafael Daltro De Oliveira, Juliette Soret-Dulphy, Lina Benajiba |
47 |
[GO] |
2021―Jan―28 |
Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19 |
Noël Zahr, Saik Urien, Benoit Llopis, Valérie Pourcher, Olivier Paccoud, Alexandre Bleibtreu, et al. (+11) Julien Mayaux, Estelle Gandjbakhch, Guillaume Hekemian, Alain Combes, Olivier Benveniste, David Saadoun, Yves Allenbach, Bruno Pinna, Patrice Cacoub, Christian Funck-Brentano, Joe-Elie Salem |
48 |
[GO] |
2021―Jan―20 |
Drug consumption during prolonged lockdown due to Covid-19 as observed in French addiction center |
Mathieu Chappuy, Marie Peyrat, Olivier Lejeune, Nathalie Duvernay, Brigitte David, Philippe Joubert, Philippe Lack |
49 |
[GO] |
2021―Jan―19 |
DPP-4 inhibitors and severe course of illness in patients with COVID-19 |
Béatrice Bouhanick, Jean-Luc Cracowski, Jean-Luc Faillie |
50 |
[GO] |
2020―Dec―26 |
A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19 |
Chia Siang Kow, Syed Shahzad Hasan |
51 |
[GO] |
2020―Nov―01 |
Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet? |
Shivshankar Malkarjun Gunjegaonkar, Thukani Sathanantham Shanmugarajan, Mohanasundaram Arunsundar, Uppuluri Varuna Naga Venkata Arjun, Kadirrel Devi, Sagar Baliram Wankhede, Velayutham Ravichandiran |
52 |
[GO] |
2020―Oct―17 |
Modifications pharmacocinétiques liées à une infection aigue. Exemples issus de la pandémie de SARS-Cov2 |
Anaëlle Chavant, Elodie Gautier-Veyret, Stéphanie Chhun, Romain Guilhaumou, Françoise Stanke-Labesque |
53 |
[GO] |
2020―Jul―22 |
COVID-19 and NSAIDs: Primum non nocere |
Joëlle Micallef, Thomas Soeiro, Annie-Pierre Jonville Béra |
54 |
[GO] |
2020―Jul―12 |
No arguments for extra risk from ibuprofen in SARS-COV2 infection |
Nicholas Moore |
55 |
[GO] |
2020―Jun―27 |
NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection |
Medine Cumhur Cure, Adem Kucuk, Erkan Cure |
56 |
[GO] |
2020―Jun―27 |
Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: a review |
Lucile Grange, Philippe Guilpain, Marie-Elise Truchetet, Jean-Luc Cracowski |
57 |
[GO] |
2020―Jun―23 |
Addictovigilance contribution during COVID-19 epidemic and lockdown in France |
Maryse Lapeyre-Mestre, Alexandra Boucher, Amelie Daveluy, Valerie Gibaja, Emilie Jouanjus, Michel Mallaret, et al. (+2) Helene Peyrière, Joëlle Micallef |
58 |
[GO] |
2020―Jun―06 |
Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic |
Jean-Luc Cracowski, Mathieu Molimard, Vincent Richard |
59 |
[GO] |
2020―May―23 |
Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence |
Matthieu Roustit, Romain Guilhaumou, Mathieu Molimard, Milou Drici, Silvy Laporte, Jean-Louis Montastruc |
60 |
[GO] |
2020―May―20 |
Renin-angiotensin-aldosterone system and COVID-19 infection |
Joachim Alexandre, Jean-Luc Cracowski, Vincent Richard, Béatrice Bouhanick |
61 |
[GO] |
2020―May―15 |
Diabetes and COVID-19 |
Béatrice Bouhanick, Jean Luc Cracowski, Jean Luc Faillie |
62 |
[GO] |
2020―May―15 |
Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France |
François Montastruc, Charles Romano, Jean-Louis Montastruc, Stein Silva, Thierry Seguin, Vincent Minville, et al. (+3) Bernard Georges, Béatrice Riu-Poulenc, Olivier Fourcade |
63 |
[GO] |
2020―May―07 |
Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection |
Joëlle Micallef, Thomas Soeiro, Jonville-Béra Annie-Pierre |
64 |
[GO] |
2020―May―07 |
“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers |
Alexandre Gérard, Serena Romani, Audrey Fresse, Delphine Viard, Nadège Parassol, Aurélie Granvuillemin, et al. (+3) Laurent Chouchana, Fanny Rocher, Milou-Daniel Drici |
65 |
[GO] |
2020―May―05 |
Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data |
Aurélie Grandvuillemin, Audrey Fresse, Clément Cholle, Samir Yamani, Anne Dautriche |